Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Brain Research

• Publication date

  2008-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.brainres.2008.02.023PMID 18374908
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease

  2007cited by this paper
• Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice.

  2006cited by this paper
• Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.

  2006cited by this paper
• Status of antioxidant defense system and expression of toxicant responsive genes in striatum of maneb- and paraquat-induced Parkinson's disease phenotype in mouse: mechanism of neurodegeneration.

  2006cited by this paper
• Nicotine induces brain CYP enzymes: relevance to Parkinson's disease.

  2006cited by this paper
• Estrogen Prevents Neuroprotection by Caffeine in the Mouse 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease

  2006cited by this paper
• Selective alterations of gene expression in mice induced by MPTP

  2005cited by this paper
• Genetic association between cytochrome P450IA1 gene and susceptibility to Parkinson's disease

  2005cited by this paper
• Involvement of cytochrome P450 2E1 in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced mouse model of Parkinson's disease

  2004cited by this paper
• Metallothionein Inducers Protect Against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Neurotoxicity in Mice

  2004cited by this paper
• Smoking, nicotine and Parkinson's disease.

  2004cited by this paper
• Effect of the knockdown of podocin mRNA on nephrin and alpha-actinin in mouse podocyte.

  2004cited by this paper
• Effect of the Knockdown of Podocin mRNA on Nephrin and α-Actinin in Mouse Podocyte

  2004cited by this paper
• Evidence for generation of oxidative stress in brain by MPTP: in vitro and in Research report

  2003cited by this paper
• Glutaredoxin is essential for maintenance of brain mitochondrial complex I: studies with MPTP

  2003cited by this paper
• Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues.

  2003cited by this paper
• [Parkinson s disease risk factors].

  2003cited by this paper
• Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism.

  2003cited by this paper
• Role of NRF2 in protection against hyperoxic lung injury in mice.

  2002cited by this paper
• A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease

  2002cited by this paper
• p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism

  2002cited by this paper
• Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice.

  2002cited by this paper
• Early and Late Gene Changes in MPTP Mice Model of Parkinson's Disease Employing cDNA Microarray

  2002cited by this paper
• Neurochemical findings in the MPTP model of Parkinson's disease

  2001cited by this paper
• Current Evidence for Neuroprotective Effects of Nicotine and Caffeine Against Parkinson’s Disease

  2001cited by this paper
• Nicotine administration reduces striatal MPP+ levels in mice.

  2001cited by this paper
• Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease

  2001cited by this paper
• Nicotinic receptors and Parkinson's disease.

  2000cited by this paper
• Free Radicals in Brain Pathophysiology

  2000cited by this paper
• [Association between cytochrome P-450 enzyme gene polymorphisms and Parkinson's disease].

  2000cited by this paper
• Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.

  2000cited by this paper
• Lipid peroxidation and tissue damage.

  1999cited by this paper
• Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist.

  1999cited by this paper
• Dopamine transporters and neuronal injury.

  1999cited by this paper
• Nicotine Prevents Experimental Parkinsonism in Rodents and Induces Striatal Increase of Neurotrophic Factors

  1998cited by this paper
• Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase.

  1998cited by this paper
• The effects of nicotine on dopamine and DOPAC output from rat striatal tissue.

  1998cited by this paper
• Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo

  1998cited by this paper
• Human glutathione transferase A4-4: an alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid peroxidation.

  1998cited by this paper
• P450 enzymes and Parkinson's disease: The story so far

  1998cited by this paper
• Preferential effects of nicotine and 4-(N-methyl-N-nitrosamine)-1-(3-pyridyl)-1-butanone on mitochondrial glutathione S-transferase A4-4 induction and increased oxidative stress in the rat brain.

  1998cited by this paper
• Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization.

  1997cited by this paper
• Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice.

  1997cited by this paper
• Presynaptic Nicotinic Modulation of Dopamine Release in the Three Ascending Pathways Studied by In Vivo Microdialysis: Comparison of Naive and Chronic Nicotine‐Treated Rats

  1997cited by this paper
• A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.

  1997cited by this paper
• Cytochrome P450 in the breast and brain: role in tissue-specific activation of xenobiotics.

  1997cited by this paper
• Psychoactive smoke

  1996cited by this paper
• Inhibition of monoamine oxidase B in the brains of smokers

  1996cited by this paper
• High inducibility of mouse renal CYP2E1 gene by tobacco smoke and its possible effect on DNA single strand breaks.

  1996cited by this paper
• Estimation of genomic complexity, heterologous expression, and enzymatic characterization of mouse glutathione S-transferase mGSTA4-4 (GST 5.7).

  1994cited by this paper
• The effect of theophylline on parkinsonian symptoms

  1994cited by this paper
• Characterization of Nicotinic Receptor‐Mediated [3H]Dopamine Release from Synaptosomes Prepared from Mouse Striatum

  1992cited by this paper
• A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter.

  1992cited by this paper
• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity : partial protection against striato-nigral dopamine depletion in C57BL/6J mice by cigarette smoke exposure and by β-naphthoflavone-pretreatment

  1991cited by this paper
• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: partial protection against striato-nigral dopamine depletion in C57BL/6J mice by cigarette smoke exposure and by beta-naphthoflavone-pretreatment.

  1991cited by this paper
• The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces changes in the heme spin state of microsomal cytochrome P-450.

  1990cited by this paper
• Functional consequences following methamphetamine-induced neuronal damage

  1989cited by this paper
• Xenobiotic metabolism in human brain--presence of cytochrome P-450 and associated mono-oxygenases.

  1989cited by this paper
• Depression of the hepatic cytochrome P-450 monooxygenase system by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1989cited by this paper
• MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.

  1987cited by this paper
• Hydroxylation of p-nitrophenol by rabbit ethanol-inducible cytochrome P-450 isozyme 3a.

  1986cited by this paper
• Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

  1984cited by this paper
• A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1983cited by this paper
• Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

  1983cited by this paper
• Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes.

  1982cited by this paper
• A rapid method for assaying the metabolism of 7-ethoxyresorufin by microsomal subcellular fractions.

  1980cited by this paper
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

  1979cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Glutathione S-transferase A. A novel kinetic mechanism in which the major reaction pathway depends on substrate concentration.

  1974cited by this paper
• Parkinson's disease

  1940cited by this paper

• In silico analysis of nicotine’s molecular targets in Parkinson’s disease

  2025cites this paper
• Small Particles, Big Potential: Polymeric Nanoparticles for Drug Delivery in Parkinson's Disease

  2024cites this paper
• Recent Advancements in Nanocarrier-assisted Brain Delivery of Phytochemicals Against Neurological Diseases

  2023cites this paper
• The impact of smoking status on clopidogrel responsiveness in patients with coronary artery disease who undergo percutaneous coronary intervention

  2023cites this paper
• Therapeutic Potential of Heterocyclic Compounds Targeting Mitochondrial Calcium Homeostasis and Signaling in Alzheimer’s Disease and Parkinson’s Disease

  2023cites this paper
• Effects of caffeinated beverage ingestion on salivary antimicrobial proteins responses to acute exercise in the heat

  2022cites this paper
• The role of heat-not-burn, snus and other nicotine-containing products as interventions for epileptic patients who take phenytoin and smoke cigarettes

  2022cites this paper
• Addressing the Neuroprotective Actions of Coffee in Parkinson’s Disease: An Emerging Nutrigenomic Analysis

  2022influential citation
• Parkinson's disease

  2021cites this paper
• Advances on Chemical Components and Biological Activities of Coffee

  2021cites this paper
• Isolongifolene mitigates rotenone-induced dopamine depletion and motor deficits through anti-oxidative and anti-apoptotic effects in a rat model of Parkinson's disease.

  2020cites this paper
• Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease

  2020cites this paper
• Cytochrome P450 expression and regulation in the brain

  2020cites this paper
• The Therapeutic Implications of Tea Polyphenols against Dopamine (DA) Neuron Degeneration in Parkinson’s Disease (PD)

  2019cites this paper
• Role of ethanolic extract of Bacopa monnieri against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced mice model via inhibition of apoptotic pathways of dopaminergic neurons.

  2017cites this paper
• MUCUNA SANJAPPAE SHOWS PROMISING ANTI-PARKINSON’S ACTIVITY BY REDUCING OXIDATIVE STRESS IN MPTP INDUCED MOUSE MODEL

  2016cites this paper
• Minocycline Rescues from Zinc-Induced Nigrostriatal Dopaminergic Neurodegeneration: Biochemical and Molecular Interventions

  2016cites this paper
• Nicotinic acetylcholine receptor availability in cigarette smokers: effect of heavy caffeine or marijuana use

  2016cites this paper
• In Invivo model of Parkinson ’ s syndrome , concurrent administrations of anti-inflammatory drugs changed behavioral deficits

  2015cites this paper
• Complex liaisons moving forward the Parkinson’s disease? An appraisal

  2015cites this paper
• Mechanism of Nanotization-Mediated Improvement in the Efficacy of Caffeine Against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonism.

  2015cites this paper
• A Correlation Study of Caffeine Content with Theobromine Content, cSNPs, and Transcriptional Expression of Three Genes in Tea Plants

  2014cites this paper
• Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism.

  2013cites this paper
• Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model.

  2013cites this paper
• Overview of Parkinson's Disease: Examing the role for the Gut-Brain-Gut axis and the use of Nutrients based on preclinical and clinical evidence

  2013cites this paper
• Synergistic effect of Mucuna pruriens and Withania somnifera in a paraquat induced Parkinsonian mouse model

  2013cites this paper
• Effect of mosquito mats (pyrethroid-based) vapor inhalation on rat brain cytochrome P450s

  2012cites this paper
• Involvement of NADPH oxidase and glutathione in zinc-induced dopaminergic neurodegeneration in rats: similarity with paraquat neurotoxicity.

  2012cites this paper
• Role of Secondary Mediators in Caffeine-Mediated Neuroprotection in Maneb- and Paraquat-Induced Parkinson’s Disease Phenotype in the Mouse

  2012cites this paper
• Single and combined effects of selected pharmaceuticals at sublethal concentrations on multiple biomarkers in Carassius auratus

  2012cites this paper
• Inflammatory Responses and Regulation in Parkinson’s Disease

  2011cites this paper
• The Promise of Neuroprotective Agents in Parkinson’s Disease

  2011cites this paper
• Oxidative stress in zinc-induced dopaminergic neurodegeneration: Implications of superoxide dismutase and heme oxygenase-1

  2011cites this paper
• Effect of nicotine on cytochrome P450 1A2 activity.

  2011cites this paper
• Effect of zinc and paraquat co-exposure on neurodegeneration: Modulation of oxidative stress and expression of metallothioneins, toxicant responsive and transporter genes in rats

  2010cites this paper
• Omics in mechanistic and predictive toxicology

  2010cites this paper
• Differential effect of environmental risk factors on postural instability gait difficulties and tremor dominant Parkinson's disease

  2010cites this paper
• Melatonin or silymarin reduces maneb‐ and paraquat‐induced Parkinson’s disease phenotype in the mouse

  2010cites this paper
• Nicotine- and caffeine-mediated changes in gene expression patterns of MPTP-lesioned mouse striatum: Implications in neuroprotection mechanism.

  2010cites this paper
• Chapter 4 Molecular Aspects of Neurotoxins in Dopaminergic Neurons

  2009cites this paper
• Neuroprotective and Neurotoxic Effects of Nicotine

  2009cites this paper
• The Expression of CYP2D22, An Ortholog of Human CYP2D6, in Mouse Striatum and Its Modulation in 1-Methyl 4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease Phenotype and Nicotine-Mediated Neuroprotection

  2009cites this paper
• Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: a proteomic approach.

  2009cites this paper
• Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.

  2009cites this paper